[1] | Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM (2010): Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer; 127: 2893–2917. |
[2] | Poustchi H., Sepanlou S.G and Esmaili S (2010): Hepatocellular Carcinoma in the World and the Middle East. Middle East Journal of Digestive Diseases; 2: 31-41. |
[3] | White DL and El-Serag HB (2011): Epidemiology of Hepatocellular Carcinoma. In: Wang XW et al., eds. Molecular Genetics of Liver Neoplasia, Cancer Genetics. Springer Science and Business Media; LLC: 51-73. |
[4] | Lehan EM and Wilson ML (2009): Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: A systematic review and meta-analysis. Int. J. Cancer; 124: 690-697. |
[5] | Lin CL and Kao JH (2013): Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol; 28: 10-17. |
[6] | Bouchard MJ and Navas-Martin S (2011): Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Letters; 305: 123–143. |
[7] | Frau M, Biasi F, Feo F and Pascale R (2010): Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Molecular Aspects of Medicine; 31: 179–193. |
[8] | Singhal A, Jayaraman M, Dhanasekaran DN and Kohli V (2012): Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol; 82 (2): 116-140. |
[9] | Wang HY and Ding J (2011): Molecular Signaling in Hepatocellular Carcinoma. In: Wang XW et al., eds. Molecular Genetics of Liver Neoplasia, Cancer Genetics. Springer Science and Business Media; LLC: 373-396. |
[10] | Di Carlo I, Mannino M, Toro A, Ardiri A and Galia A (2012): Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. World J Surg Oncol., 6: 10:79. |
[11] | Giannini EG1, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M, Borzio F, Caturelli E,Chiaramonte M and Trevisani F (2012): Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.Hepatology; 56(4): 1371-9. |
[12] | Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G and Bertino N (2012): Hepatocellualar carcinoma serum markers. Semin Oncol., 39: 410-433. |
[13] | Stokes CS, Volmer DA, Grunhage Fand Lammert F (2013): Vitamin D in chronic liver disease. Liver Int., 33:338-352. |
[14] | Kitson MT and Roberts SK (2012): D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol., 57: 897-909. |
[15] | Chiang KC, Yeh CN, Chen MFand Chen TC (2011): Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol., 26: 1597–1603. |
[16] | Vanoirbeek E, Krishnan A, Eelen G, Verlinden L, Bouillon R, Feldman D and Verstuyf A (2011) The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab., 25: 593–604. |
[17] | Yuan-Ping Han, Ming Kong, Sujun Zheng, Yan Ren, Longdon Zhu, Hongbo Shi and Zhongping Duan (2013):Vitamin D in liver diseases: From mechanisms to clinical trials .Journal of Gastroenterology and Hepatology 2013; 28 (Suppl. 1): 49–55. |
[18] | Forner A, Llovet JMand Bruix J (2012): Hepatocellular carcinoma. Lancet., 379: 1245-1255. |
[19] | Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulou A, Misirli G, Trichopoulos D, Berrino F, Vineis P, Panico S, Palli D, Tumino R, Ros MM, van Gils CH, Peeters PH, Brustad M, Lund E, Tormo MJ, Ardanaz E, Rodrı´guez L, Sa´nchez MJ, Dorronsoro M, Gonzalez CA, Hallmans G, Palmqvist R, Roddam A, Key TJ, Khaw KT, Autier P, Hainaut Pand Riboli E (2010): Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 340: b5500. |
[20] | Chen W, Dawsey SM, Qiao YL, Mark SD, Dong ZW, Taylor PR, Zhao Pand Abnet CC (2007): Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer; 97: 123–128. |
[21] | Abnet CC, Chen Y, Chow WH, Gao YT, Helzlsouer KJ, Le Marchand L,McCullough ML, Shikany JM, Virtamo J, Weinstein SJ, Xiang YB, Yu K, Zheng W, Albanes D, Arslan AA, Campbell DS, Campbell PT, Hayes RB, Horst RL, Kolonel LN, Nomura AM, Purdue MP, Snyder K and Shu XO (2010): Circulating 25-hydroxyvitamin D and risk of esophageal and gastric cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol., 172: 94–106. |
[22] | Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM and Hayes RB (2008): Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst., 100: 796–804. |
[23] | Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, Weinstein SJ, McCullough ML, Purdue MP, Shu XO, Snyder K, Virtamo J, Wilkins LR, Yu K, Zeleniuch-Jacquotte A, Zheng W, Albanes D, Cai Q, Harvey C, Hayes R, Clipp S, Horst RL, Irish L, Koenig K, Le Marchand L and Kolonel LN (2010): Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol., 172: 81–93. |
[24] | Wang JB, Abnet CC, Chen W, Dawsey SM, Fan JH and Yin LY (2013): Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials:a nested case-control study. Br J Cancer; 109:1997-2004. |
[25] | Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD (2009): Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol., 14(27): 4300-4308. |
[26] | Lange CM, Miki D, Ochi H, Nischalke H-D and Bojunga J (2013): Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS ONE; 8(5): e64053. |
[27] | Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA and Schaalan MF (2013): Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol., 10: 380- 386. |
[28] | Finkelmeier F1, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper Aand Waidmann O (2014): Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther.,9(10):1204-12. |
[29] | Mansoor S, Habib A , Ghani F , Fatmi Z, Badruddin S , Mansoor S, Siddiqui I and Jabbar A (2010): Prevalence and significance of vitamin D deficiency and insufficiency among apparently healthy adults. Clinical Biochemistry Journal; CLB07508:5; 4c. |
[30] | Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007; 5:513–520. |
[31] | Chiang KC, Yeh CN, Chen MF, Chen TC (2011) Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol 26: 1597–1603. |
[32] | Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V (2010) The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 79: 1–9 |
[33] | Caputo A, Pourgholami MH, Akhter J and Morris DL (2003): 1, 25- Dihydroxyvitamin D(3) induced cell cycle arrest in the human primary liver cancer cell line HepG2. Hepatol Res., 26: 34–39. |
[34] | Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, Fumolo E, Bignulin S, Cmet S, Minisini R, Pirisi M and Toniutto P (2010): Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol., 16(24): 3016–3024. |
[35] | Samir G, Stephen Band Jeffrey K (2003): Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis. Annals of Internal Medicine; 139(1): 46-50. |